CN Patent

CN110305138B — 一种治疗癌症的化合物及其用途

Assigned to Haichuang Pharmaceutical Co Ltd · Expires 2021-04-23 · 5y expired

What this patent protects

如式I所示的化合物、或其光学异构体、或其药学上可接受的盐、或其水合物、或其溶剂合物：R 1 ‑R 20 分别独立选自氢、氘。本发明提供的各种化合物及其盐类、水合物或溶剂合物，具备抗癌活性和更好的代谢稳定性。尤其对NTRK融合突变的癌症有显著的疗效。

USPTO Abstract

如式I所示的化合物、或其光学异构体、或其药学上可接受的盐、或其水合物、或其溶剂合物：R 1 ‑R 20 分别独立选自氢、氘。本发明提供的各种化合物及其盐类、水合物或溶剂合物，具备抗癌活性和更好的代谢稳定性。尤其对NTRK融合突变的癌症有显著的疗效。

Drugs covered by this patent

larotrectinib-sulfate (LAROTRECTINIB SULFATE)

Patent Metadata

Patent number: CN110305138B
Jurisdiction: CN
Classification: —
Expires: 2021-04-23
Drug substance claim: No
Drug product claim: No
Assignee: Haichuang Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.